Quality of life and economic cost of multiple sclerosis;L'évaluation médico-économique dans la sclérose en plaques

Revue Neurologique

Volumn 160, Issue 1, 2004, Pages 23-34

  Grimaud, J ^a,b,c   Auray, J P ^a,b   Barre Coignet, A ^b   Berthier, E ^b   Borgel, F ^b   Brault, J L ^b   De Marco, O ^b   Diot, E ^b   Fayolle, H ^b   Gibert, I ^b   Guennoc, A M ^b   Leche J ^b   Lemaire, J F ^b   Magy, L ^b   Moreau, T ^b   Neuschwander, Ph ^b   Noblet, M P ^b   Pomet, E ^b   Renard, J F ^b   Rondepierre, P ^b   Rumbach, L ^b   more..

^a UNIVERSITÉ LYON 1   (France)

^b Hôpital Louis Pasteur ^*

^c Hopital Louis Pasteur   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE;

BUDGET; COGNITIVE DEFECT; COST BENEFIT ANALYSIS; COST OF ILLNESS; FINANCE; HUMAN; MULTIPLE SCLEROSIS; PATIENT CARE; PHYSICAL DISABILITY; QUALITY OF LIFE; REVIEW; SOCIAL STATUS;

EID: 12144287969     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(04)70844-9     Document Type: Review

References (250)

1. AISEN ML, SEVILLA D, FOX N, BLAU A. (1996). Inpatient rehabilitation for multiple sclerosis. J Neurol Rehabil, 10: 43-44.
2. AMATO MP, PONZIANI G, ROSSI F, LIEDL CL, STEFANILE C, ROSSI L. (2001). Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler, 7: 340-344.
3. AMATO MP, BATTAGLIA MA, CAPUTO D, et al. (2002). The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol, 249: 152-163.
4. ANDERSEN EM, MEYERS AR. (2000). Health-related quality of life outcomes measures. Arch Phys Med Rehabi, 181: S30-S45.
5. ANDERSON RB, TESTA MA. (1994). Symptom distress checklists as a component of quality-of-life measurement: comparing prompted reports by patient and physician with concurrent adverse event reports via the physician. Drug Inf J, 28: 89-114.
6. ARNOLDUS JHA, KILLESTEIN J, PFENNINGS LEMA, JELLES B, UITDEHAAG BMJ, POLMAN CH. (2000). Quality of life during the first 6 months of interferon-β treatment in patients with MS. Mult Scler, 6: 338-342.
7. ARONSON KJ, CLEGHORN G, GOLDENBERG E. (1996). Assistance arrangements and use of services among persons with multiple sclerosis and their caregivers. Disabil Rehabil, 18: 354-361.
8. ARONSON KJ. (1997). Quality of life among persons with multiple sclerosis and their caregivers. Neurology, 48: 74-80.
9. ASCHE CV, CHAN B, COYTE PC. (1997). Economic consequences of multiple sclerosis for Canadian. Acta Neurol Scand, 95: 268-274.
10. BAUER HJ, KRTSCH U, SCHIPPER S, ECKHARDT J, MINZLOFF H, NATER B. (1984). Disability rating with the IFMSS scales. Acta Neurol Scand, 70: 46-55.
11. BEN-ZACHARIA AB, LUBLIN FD. (2001). Palliative care in patients with multiple sclerosis. Neurol Clin, 19: 801-827.
12. BENEDICT RHB, SHAPIRO A, PRIORE R, MILLER C, MUNSCHAUER F, JACOBS L. (2000). Neuropsychological counseling improves social behavior in cognitively-impaired multiple sclerosis patients. Mult Scler, 6: 391-396.
13. BÉNETON C, RUMBACH L. (1999). Impact social et économique de la sclérose en plaques. Rev Prat, 49: 1890-1893.
14. BERGNER M, BOBBITT RA, KRESSEL S, POLLARD WE, GILSON BS, MORRIS JR. (1976). The Sickness Impact Profile: conceptual formulation and mehodology for the developpment of a health status measure. Int J Health Serv, 6: 393-415.
15. BERGNER M, BOBBITT RA, CARTER WB, GILSON BS. (1981). The Sickness Impact Profile: developpment and final revision of a health status measure. Med Care, 19: 787-805.
16. BLAIVAS JG, HOLLAND NJ, GIESSER B, LAROCCA N, MADONNA M, SCHEINBERG L. (1984). Multiple sclerosis bladder: studies and care. Ann NY Acad Sci, 436: 328-345.
17. BLUMHARDT LD, WOOD C. (1996). The economics of multiple sclerosis: A cost of illness study. Br J Med Econ, 10: 99-118.
18. BORGEL F. (2001). La prise en charge rééducative dans le suivi neurologique du patient SEP. Rev Neurol, (Pans) 157: 1135-1138.
19. BOURDETTE DN, PROCHAZKA AV, MITCHELL W, LICARI P, BURKS J and the VA Multiple Sclerosis Rehabilitation Study Group. (1993). Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. Arch Phys Med Rehabil, 74: 26-31.
20. BRADLEY EM, THOMPSON RP, WOOD PHN. (1978). The prevalence and severity of major disabling conditions: a reappraisal of the government social survey on the handicapped and impaired un Great Britain. Int J Epidemiol, 7: 175-181.
21. BRIGGS A, GRAY A. (2000). Using cost effectiveness information. BMJ, 320: 246.
22. BROCHET B. (2001). Principales échelles utilisées en pratique neurologique courante: sclérose en plaques. Encycl Méd Chir (Éditons Scientifiques et Médicales Elsevier SAS, Paris, tous droits réservés), Neurologie, 17-035-A-81, 9p.
23. BRODY DS. (1980). The patient's role in clinical decision-making. Ann Intem Med, 93: 718-722.
24. BROWN JR. (1969). Recent studies in multiple sclerosis: inferences on rehabilitation and employability. Mayo Clin Proc, 44: 758-765.
25. BROWN MG, MURRAY TJ, FISK J, SKETRIS I. (1996a). Multiple sclerosis health care costs in Nova Scotia: A population-based life-cycle study. Halifax, Nova Scotia: Department of Community Health and Epidemiology, Dalhousie University.
26. BROWN MG, MURRAY TJ, FISK JD, et al. (1996b). A therapeutic and economic assessment of Betaseron® in multiple sclerosis. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA).
27. BROWN MG, MURRAY TJ, SKETRIS IS, FISK JD, LEBLANC JC, SCHWARTZ CE, SKEDGEL C (2000). Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression: first estimates. Int J Technol Assess Health Care, 16: 751-767.
28. Brunet DG, Hopman WM, Singer MA, Edgar CM, MacKenzie TA. (1996). Measurement of health-related quality of life in multiple sclerosis patients. Can J Nerurol Sci, 23: 99-103.
29. BRYANT J, CLEGG A, MILNE R. (2001). Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost? J Neurol Neurosurg Psychiatry, 70: 574-579.
30. CAMFIELD L, BEN-SHLOMO Y, WARNER TT AND THE EPIDEMIOLOGICAL STUDY of DYSTONIA IN EUROPE COLLABORATIVE GROUP. (2002). Impact of cervical dystonia on quality of life. Mov Disord, 17: 838-841.
31. CARRÈRE MO, MOUMJID-FERDJAOUI N, CHARAVEL M, BRĖMOND A. (2000). Eliciting patients' preferences for adjuvant chemotherapy in breast cancer: development and validation of a bedside decision-making instrument in a French Regional Cancer Centre. Health Expect, 3: 97-113.
32. CARTON H, LOOS R, PACOLET J, VERSIECK K, VLIETINCK R. (1998). Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium). J Neurol Neurosurg Psychiatry, 64: 444-450. (Reply: Forbes RB, Swingler RJ. pp 256-257).
33. CATANZARO M, WEINERT C. (1992). Economic status of families living with multiple sclerosis. Int J Rehabil Res, 15: 209-218.
34. CELLA DF, DINEEN K, ARNASON B, et al. (1996). Validation of the functional assessment of multiple sclerosis quality of life insrument. Neurology, 47: 129-139.
35. CERVERA-DEVAL J, MORANT-GUILLEN MP, FENOLLOSA-VASQUEZ P, SERRA-ESCORIHUELA M, VILCHEZ-PADILLA J, BURGUERA J. (1994). Social handicaps of multiple sclerosis and their relation to neurological alterations. Arch Phys Med Rehabil, 7: 1223-1227.
36. CHANG CH, CELLA D, FERNANDEZ O et al. (2002). Quality of life in multiple sclerosis patients in Spain. Mult Scler, 8: 527-531.
37. CHIRIKOS TN. (1989). Aggregate economic losses from disability in the United State: a preliminarey assay. Milbank Quaterly, 67: 59-91.
38. COHEN JA, CUTTER GR, FISHER JS et aL for the IMPACT Investigators. (2002). Benefit of interferon-β1a on MSFC progression in secondary progressive MS. Neurology, 59: 679-687.
39. CONFAVREUX C, VUKUSIC S, MOREAU T, ADELEINE P. (2000). Relapses and progression of disability in multiple sclerosis. N Engl J Med, 343: 1430-1438.
40. COTTRELL DA, KREMENCHUTZKY M, RICE GP, KOOPMAN WJ, HADER W, BASKERVlLLE J, EBERS GC. (1999). The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain, 122: 625-39.
41. COYLE CP, SANTIAGO MC, SHANK JW, MA GX, BOYD R. (2000). Secondary conditions and women with physical disabilities: a descriptive study. Arch Phys Med Rehabil, 81: 1380-1387.
42. CUTTER GR, BAIER ML, RUDICK RA, et al. (1999). Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain, 122: 871-882.
43. DE ANDRES C, GUILLEM A. (2000). Una aproximacion sobre la calidad de vida en pacientes con esclerosis multiple. Rev Neurol, 30: 1229-1234.
44. DESROSIER MB, CATANZARO M, PILLER J. (1992). Living with chronic illness: social support and the well spouse perspective. Rehabil Nurs, 17: 87-91.
45. DETOURNEY B. (2002). The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis (Editorial). Value Health 5: 1-2. Réponse: Hutton J (2002). Value Health, 5: 114-115.
46. DETOURNEY B. (2002). The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis (Editorial). Value Health 5: 1-2. Réponse: Hutton J (2002). Value Health, 5: 114-115.
47. DEVELOPMENT AND EVALUATION COMMITTEE. (1997). Interferon beta-1a in relapsing-remitting multiple sclerosis. Report N° 77, The Wessex Institute for Health Research and Development.
48. DEVINS GM, EDWORTHY SM, SELAND TP, KLEIN GM, PAUL LC, MANDIN H. (1993). Differences in illness intrusiveness across rheumatoid arthritis, end-stage renal disease, and multiple sclerosis. J Nerv Ment Dis, 181: 377-381.
49. DI FABIO RP, CHOI T, SODERBERG J, HANSEN CR. (1997). Health related quality of life for patients with progressive multiple sclerosis: influence of rehabilitation. Phys Ther, 77: 1704-1716.
50. Di FABIO RP, SODERBERG J, CHOI T, HANSEN CR, SHAPIRO RT. (1998). Extended outpatient rehabilitation: its influence on symptom frequency, fatigue, and functional status for persons with progressive multiple sclerosis. Arch Phys Med Rehab, 79: 141-146.
51. DRUMMOND MF, O'BRIEN B, STODDART GL, TORRANCE GW. (1997). Methods for the Economic Evaluation of Health Care Programmes 2nd edn. Oxford Medical Publiocations, Oxford.
52. DURU G, AURAY JP, BÉRESNIAK A, LAMURE M, PAINE A, NICILOYANNIS N. (2002). Limitations of the methods used for calculating quality-adjusted life-year values. Pharmacoeconomics, 20: 463-473.
53. EBRAHIM S, REDFERN J. (1999). Stroke care: A matter of chance. A National Survey of Stroke service London: The Stroke Association.
54. ELIAS SB, ELSTON-LAFATA J, SCHULTZ LR, REUTHER J, MOON CH. (2002). Beta interferon use among multiple sclerosis patients in a managed care setting: demographics, cost of care, utilization, health status, and quality of life (Poster S12.004). Neurology, 58: A84.
55. EUROPEAN STUDY GROUP ON INTERFERON BETA-lb IN SECONDARY PROGRESSIVE MS. (1998). Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet, 352: 1491-1497.
56. FAWCETT J, HANSON MJS, RILEY-LAWLESS K, SIDNEY JS. (1996). Alternative therapies and multiple sclerosis: two case reports. Altern Ther Health Med, 2: 67-69.
57. FEIGENSON JS, SCHEINBERG L, CATALANO M, POLKOW L, MANTEGAZZA PM, FEIGENSON WD, LAROCCA NG. (1981). The cost-effectivness of multiple sclerosis rehabilitation: A model. Neurology, 31: 1316-1322.
58. FEINSTEIN A. (2002). An examination of suicidal intent in patients with multiple sclerosis. Neurology, 59: 674-678.
59. FENDER P, PAITA M, SALANAVE B, GANAY D, ALLEMANO H. (2000). Dépenses du Régime général de l'Assurance-Maladie en 1994 pour trente affections de longue durée. Santé Publique, 12: 5-19.
60. FERDJAOUl N, CARRÉRE MO, CHARAVEL M, et al. (1999). La prise en compte des préférences des patients dans la décision thérapeutique en cancérologie: développement d'un tableau de décision. Journal d'Économie Médicale, 5: 327-342.
61. FISHMAN P, VON KORFF M, LOZANO P, HECHT J. (1997). Chronic care costs in managed care. Health Aff (Millwood), 16: 239-247.
62. FLETCHER A, GORE S, JONES D, FITZPATRICK R, SPIEGELHALTER D, Cox D. (1992). Quality of life measures in health care. 2: Design, analysis, and interpretation. BMJ, 305: 1145-1148.
63. FORBES RB, LEES A, WAUGH N, SWINGLER RJ. (1999). Population based cost utility of interferon beta-lb in secondary progressive multiple sclerosis. BMJ, 319: 1529-1533.
64. FORD HL, GERRY E, TENNANT A, WHALLEY D, HAIGH R, JOHNSON MH. (2001). Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin Rehabil, 15: 247-258.
65. FREEMAN JA, LANGDON DW, HOBART JC, et al. (1996a). Inpatient rehabilitation in multiple sclerosis undergoing inpatient rehabilitation. J Neuro Rehabil, 10: 185-194.
66. FREEMAN JA, LANGDON DW, HOBART JC, THOMPSON AJ. (1996b). Health-related quality of life in people with multiple sclerosis undergoing inpatient rehabilitation. J Neurol Rehabil, 10: 185-194.
67. FREEMAN JA, LANGDON DW, HOBART JC, THOMPSON AL. (1997). The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol, 42: 236-244.
68. FREEMAN JA, THOMPSON AJ. (1998). Inpatient rehabilitation in multiple sclerosis. Int MS, J 5: 16-23.
69. FREEMAN JA, LANGDON DW, HOBART JC, THOMPSON AJ. (1999). Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community? Neurology, 52: 50-56.
70. FREEMAN JA, THOMPSON AJ. (2000). Community services in multiple sclerosis: still a matter of chance. J Neurol Neurosurg Psychiatry, 69: 728-732.
71. FREEMAN JA, HOBART JC, LANGDON DW, THOMPSON AJ. (2000). Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry, 68: 150-156.
72. FREEMAN JA, HOBART JC, THOMPSON AJ. (2001a). Does adding MS-specific items to a generic measure (the SF-36) improve measurement? Neurology, 57: 68-74.
73. FREEMAN JA, THOMPSON AJ, FITZPATRICK R, et al. (2001b). Interferon-β1b in the treatment of secondary progressive MS. Impact on quality of life. Neurology, 57: 1870-1875.
74. FRÜHWALD S, LOEFFLER-STASTKA H, EHER R, SALETU B, BAUMHACKI U. (2001). Depression and quality of life in multiple sclerosis. Acta Neurol Scand, 104: 257-261.
75. GAGE BF, CARDINALLI AB, ALBERS GW, OWENS DK. (1995). Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with non-valvular atrial fibrillation. J Am Med Assoc, 274: 1839-1845.
76. GEDIZLIOGLU M, MAVIOGLU H, UZUNEL F, et al. (1999). Impact of multiple sclerosis on family and employment: a prospective study in Agean district, Turkey (Abstract P194). Mult Scler, 5: S50.
77. GENEVIE L, KALLOS JE, STRUENING EL. (1987). Job retention among people with multiple sclerosis. J Neurol Rehabil, 1: 131-135.
78. GETSIOS D, CARO JJ, CARO G, ISHAK K, FOR THE AHEAD STUDY GROUP. (2001). Assessment of health economics in Alzheimer's disease (AHEAD). Galantamine treatment in Canada. Neurology, 57: 972-978.
79. GIANIMO JM, YORK MM, PAICE JA, SHOTT S. (1998). Quality of life: effect of reduced spasticity from intrathecal baclofen. J Neurosci Nurs, 30: 47-54.
80. GOLD SM, HEESEN C, SCHULZ H, et al. (2001). Disease specific quality of life instruments in multiple sclerosis: Validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS). Mult Scler, 7: 119-130.
81. GOTTBERG K, EINARSSON U, FREDRIKSON S et al. (2002). Multiple sclerosis in Stockholm County. A pilot study of utilisation of health-care resources, patient satisfaction with care and impact on family caregiver. Acta Neurol Scand, 106: 241-247.
82. GOTTBERG K, GARDULF A, FREDRIKSON S. (2000). Interferon-beta treatment for patients with multiple sclerosis: the patients'perceptions of the side-effects. Mult Scler, 6: 349-354.
83. GREGORY RJ, EISLER P, FIRTH S. (1996). Caregivers of people with multiple sclerosis: a survey in New Zealand. Rehabil Nurs, 21: 31-37.
84. GRIMA DT, TORRANCE GW, FRANCIS G, RICE G, ROSNER AJ, LAFORTUNE L. (2000). Cost and health related quality of life consequences of multiple sclerosis. Mult Scler, 6: 91-98.
85. GRIMAUD J, PAGEOT N, ROVARIS M. (2001). Parallèles entre les aspects cliniques et IRM dans la sclérose en plaques. Rev Neurol (Paris), 157: 884-890.
86. GRONNING M, HANNISDAL E, MELLGREN SI. (1990). Multivariate analyses of factors associated with unemployment in people with multiple sclerosis. J Neurol Neurosurg Psychiatry, 53: 388-390.
87. GRUDZINSKI AN, HAKIM Z, Cox ER, BOOTMAN JL. (1999). The economics of multiple sclerosis. Distribution of costs and relationship to disease severity. Pharmacoeconomics, 15: 229-240.
88. GULICK EE. (1997). Correlates of quality of life among persons with multiple sclerosis. Nurs Res, 46: 305-311.
89. GUNDERSON CH. (1995). The impact of new pharmaceutical agents on the cost of neurologic care. Neurology, 45: 569-572.
90. GUYATT G, FEENY DH, PATRICK DL. (1991). Issues in quality-of-life measurement in clinical trials. Control Clin Trials, 12: 81S-90S.
91. HAINSWORTH MA. (1996). Helping spouses with chronique sorrow related to multiple sclerosis. J Psychosoc Nurs Ment Health Serv, 34: 36-40.
92. HARWOOD DG, SULTZER DL. (2002). «Life is not worth living»: Hopelessness in Alzheimer's disease. J Geriatr Psychiatry Neurol, 15: 38-43.
93. HENRIKSSON F, FREDRIKSON S, MASTERMAN T, JÖNSSON B. (2001). Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol, 8: 27-35.
94. HENRIKSSON F, JÖNSSON B. (1998). The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeconomics, 13: 597-606.
95. HENRIKSSON F, JÖNSSON B. (2000). The economic evaluation and consequences of multiple sclerosis. Int MS, J 7: 9-17.
96. HERMANN BP, VICKREY B, HAYS RD, et al. (1996). A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Res, 25: 113-118.
97. HEWER RL. (1997). The economic impact of neurological illness on the health and wealth of the nation and of individuals. J Neurol Neurosurg Psychiatry, 63: S19-S23.
98. HILL JW, FUTTERMAN R, DUTTAGUPTA S, MASTEY V, LLOYD JR, FILLIT H. (2002). Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare. Neurology, 58: 62-70.
99. HOBART J, FREEMAN J, THOMPSON A. (2000). Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain, 123: 1027-1040.
100. HOBART J, LAMPING D, FITZPATRICK R, RIAZI A, THOMPSON A. (2001a). The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain, 124: 962-973.
101. HOBART J, FREEMAN J, LAMPING D, FIRTZPATRICK R, THOMPSON A. (2001b). The SF-36 in multiple sclerosis: why basic assumptions must be tested. J Neurol Neurosurg Psychiatry, 71: 363-370.
102. HOLLOWAY RG. (1996). Cost-effectiveness analysis: what is it and how will it influence neurology. Ann Neurol, 39: 818-823.
103. HOLLOWAY RG, RINGEL SP, BERNAT JL, KERAN CM, LAWYER BL. (2000). US neurologists attitudes on rationing. Neurology, 55: 1492-1497.
104. HOLMES J, MADGWICK T, BATES D. (1995). The cost of multiple sclerosis. B J Med Econ, 8: 181-193.
105. HUGHES TE, LARSON LN. (1991). Patient involvement in health care. A procedural justice viewpoint. Med Care, 29: 297-303.
106. HUNTLEY A, ERNST E. (2000). Complementary and alternative therapies for treating multiple sclerosis symptoms: a systematic review. Complement Ther Med, 8: 97-105.
107. INMAN RP. (1984). Disability indices, the economic costs of illness, and social insurance: The case of multiple sclerosis. Acta Neurol Scand, 70: 46-55.
108. INMAN RP. (1987). The economic consequences of a debilitating illness: the case of multiple sclerosis. Rev Econ Stat, 69: 651-660.
109. JANARDHAN V, BAKSHI R. (2000). Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis. Arch Neurol, 57: 1485-1491.
110. JONSSON B. (1995). The economic cost of multiple sclerosis in Sweden. Stockholm: Stockholm School of Economics, The Economic Research Institute. EFI research paper No. 6551.
111. KANTARCI O, SIVA A, ERAKSOY M, et al. (1998). Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology, 51: 765-772.
112. KENDRICK M, JOHNSON KI. (2000). Long term treatment of multiple sclerosis with interferon-β may be cost effective. Pharmacoeconomics, 18: 45-53.
113. KERSTEN P, MULLEE MA, SMITH JAE, MCLELLAN L, GEORGE S. (1999). Generic health status measures are unsuitable for measuring health status in severly disabled people. Clin Rehabil, 13: 219-228.
114. KETELAER P. (1980). La sclérose en plaques dans la société. Rev Prat, 30: 2109-2112.
115. KIND P. (1996). The EuroQol instrument: an index of health-related quality of life. In Spilker B ed. Quality of life and pharacoeconomics in clinical trials. (2nd ed). Philadelphia: Lippincott-Raven, p. 191-201.
116. KOBELT G, JÖNSSON L, HERIKSSON F, FREDRIKSON S, JÖNSSON B. (2000a). Cost-utility analysis of interferon beta-1 b in secondary progressive multiple sclerosis. Int J Technol Assess Health Care, 16: 768-780.
117. KOBELT G, LINDGREN P, SMALA A et al. (2001). The German cost of MS study group. Costs and quality of life in multiple sclerosis. A cross-sectional study in Germany. HEPAC, 2: 60-68.
118. KOBELT G, LINDGREN P, PARKIN D et al. (2000b). Costs and quality of life in multiple sclerosis. A cross-sectional observational study in the United Kingdom. Stockholm School of Economics, 2000: EFI Research Report 398.
119. KORNBUTH AB, LAROCCA NG, BAUM HM. (1986). Employment in individuals with multiple sclerosis. Int J Rehab Research, 9: 155-165.
120. KRAFT GH. (1999). Rehabilitation still the only way to improve function in multiple sclerosis. Lancet, 354: 2016-2017.
121. KUJALA P, PORTIN R, RUUTIAINEN J. (1997). The progress of cognitive decline in multiple sclerosis. A controlled 3-years follow-up. Brain, 120: 289-297.
122. KURTZKE JF. (1983). Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 33: 1444-1452.
123. LAMPL C, KLINGLER D, DEISENHAMMER E, HAGENBICHLER E, NEUNER L, PESEC B. (2001). Hospitalization of patients with neurological disorders and estimation of the need of beds and of the related costs in Austria's non-profit hospitals. Euro J Neurol, 8: 701-706.
124. LANSKA DJ. (2002). Time is money - or is it? Estimating the costs of informal caregiving. Neurology, 58: 1718-1719.
125. LAROCCA N, KLAB R, SCHEINBERG L, KENDALL R. (1985). Factors associated with unemployment of patients. J Chron Dis, 38: 203-210.
126. LAROCCA NG, KALB RC. (1992). Efficacy of rehabilitation in multiple sclerosis. J Neurol Rehabil, 6: 147-155.
127. LAROCCA NG, RITVO PG, MILLER DM, FISCHER JS, ANDREWS H, PATY DW. (1996). «Quality of life»assessment in multiple sclerosis clinical trials: current status and strategies for improving multiple sclerosis clinical trial design. In: Goodkin DE, Rudick RA, editors. Multiple sclerosis: advances in clinical trial design, treatment and future perspectives. London: Springler-Verlag, p. 145-160.
128. LEPLÈGE A, MESBAH M, MARQUIS P. (1995). Analyse préliminaire des propriétés psychométriques de la version française d'un questionnaire international de mesure de qualité de vie: le MOS-SF36 (version 1.1). Rev Epidem et Santé Publ, 43: 371-379.
129. LUI C, WAN PO AL, BLUMHARDT LD. (1998). 'Summary measure'statistic for assessing the outcome of treatment trials in relapsing-remiting multiple sclerosis. J Neurol Neurosurg Psychiatry, 64: 726-729.
130. MACDONALD R. (2000). Cost effectiveness of mutiple sclerosis drugs remains unknown. BMJ, 321: 399.
131. MARISSAL JP, HAUTECOEUR P. (2000). Les répercussions économiques de la sclérose en plaques. Pathol Biol (Paris), 48: 139-150.
132. MATHIOWETZ V, MATUSKA KM, MURPHY ME. (2001). Efficacy of an energy conservation course for persons with multiple sclerosis. Arch Phys Med Rehabil, 82: 449-456.
133. MCCORMICK WC, HARDY J, KUKULL WA, BOWEN JD, TERI L, ZITER S, LARSON EB. (2001). Healthcare utilization and costs in managed care patients with Alzheimer's disease during the last few years of life. JAGS, 49: 1156-1160.
134. MCDONNELL GV, HAWKINS SA. (2001). An assessment of the spectrum of disability and handicap in multiple sclerosis: a population-based study. Mult Scler, 7: 111-117.
135. MCGOWN L, MCWHINNIE W. (1995). MS patient survey: Cost and reimbursement of treatment - The cost of multiple sclerosis. Montreal: Concordia University Pharmaceutical Management Centre, Concordia University.
136. MERKELBACH S, SITTINGER H, KOENIG J. (2002). Is there a differential impact of fatigue and physical disability on quality of life in multiple sclerosis? J Nerv Ment Dis, 190: 388-393.
137. MESSMER UCCELLI M, BATTAGLIA MA, ZAGAMI P, SOLARO C. (2002). The interdisciplinary approach to the treatment of multiple sclerosis patients in Italy: an aspiration or a reality? Mult Scler, 8: 36-39.
138. MEYERS AR, ANDRESEN EM. (2000). Enabling our instruments: accomodation, universal design, and access to participation in research. Arch Phys Med Rehabil, 81: S5-S9.
139. MEYERS AR, ANDRESEN EM, HAGGLUND KJ. (2000). A model of outcomes research: spinal cord injury. Arch Phys Med Rehabil, 81: S81-S90.
140. MEYER-ROSBERG K, BURCKHARDT CS, HUIZAR K, KVARNSTROM A, NORDFORS LO. (2001). A comparison of the SF-36 and Nottingham Health Profile in patients with chronic neuropathic pain. Eur J Pain, 5: 391-403.
141. MILANESE C. (2000). Unmet needs in multiple sclerosis: the role of community services (Editorial). J Neurol Neurosurg Psychiatry, 69: 715-717.
142. MILLER DM, RUDICK RA, CUTTER G, BAIER M, FISCHER JS. (2000). Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol, 57: 1319-1324.
143. MINDEN SL, MARDER WD, HARROLD LN, DOR A. (1993). Multiple sclerosis: A statistical portrait. A compendium of data on demographics, disability, and health services utilization in the United States. Report for the National Multiple Sclerosis society. Cambridge, MA: Abt Associates Inc.
144. MINDEN SL, SCHIFFER RB. (1990). Affective disorders in multiple sclerosis: review and recommendations for clinical research. Arch Neurol, 47: 98-104.
145. MINDERHOUD JM, CASSEL H, PRANGE AJA. (1984). Proposal for summing the incapacity status or environnemental status scores. Acta Neurol Scand, 70: 87-91.
146. MIRALLES A, FUENTES E, DIEZ TEJEDOR E, BARREIRO P. (2001). Analysis of fatigue and quality of life in relapsing-remitting multiple sclerosis treated with beta interferon. (Poster 429). J Neurol, 248: II/114.
147. MITCHELL JN. (1981). Multiple sclerosis and the prospects of employment. J Soc Occup Med, 31: 134-138.
148. MOHR DC, LIKOSKY W, BOUDEWYN AC, MARIETTA P, DWYER P, VAN DER WENDE J, GOODKIN DE. (1998). Side-effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. Mult Scler, 4: 487-489.
149. MOORER P, SUURMEIJER TH, ZWANIKKEN CP. (2000). Health care utilization by people with multiple sclerosis in The Netherlands: results of two separate studies. Disabil Rehabil, 22: 695-701.
150. MOORER P, SUURMEIJER ThPBM, FOETS M, MOLENAAR IW. (2001). Psychometric properties of the RAND-36 among three chronic diseases (multiple sclerosis, rhumatic diseases and COPD) in The Netherlands. Qual Life Rese, 10: 637-645.
151. MULTIPLE SCLEROSIS INTERFERON β-1a (Avonex®) QUALITY OF LIFE (QoL) FRENCH STUDY GROUP. (1999). Quality of life of MS patients before interferon b-1a treatment (Abstract P191). Mult Scler, 5: S49.
152. MURPHY N, CONFAVREUX C, HAAS J, et al. (1998). Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics, 13: 607-622.
153. MYHR KM, RIISE T, VEDELER C, NORTVEDT MW, Gronning M, Midgard R, Nyland HI. (2001). Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler, 7: 59-65.
154. NATIONAL ANALYSIS, Inc. (1981). Incidence, prevalence and costs of multiple sclerosis. Philadelphia: National Analysis, Inc.
155. NEILLEY LL, GOODIN DS, GOODKIN DE, HAUSER DL. (1996). Side-effect profile of interferon beta-1b in MS: results of an open label trial. Neurology, 46: 552-554.
156. NICHOLSON T, MILNE R. (1999). Beta interferons (1a and 1b) in relapsing-remitting and secondary progressive multiple sclerosis. DEC report No. 98. Southampton: Wessex Institute for Health Research and Development.
157. NICHOLSON T, STEIN K. (1997). Interferon beta-1a in relapsing-remitting multiple sclerosis. DEC report No. 77, Southampton: Wessex Institute for Health Research and Development.
158. NOONAN CW, KATHMAN SJ, WHITE MC. (2002). Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology, 58: 136-138.
159. NORTVEDT MW, RIISE T, MYER KJ, NYLAND HI. (1999a). Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology, 53: 1098-1103.
160. NORTVEDT MW, RIISE T, MYER KM, NYLAND HI, HANESTAD BR. (1999b). Type 1 interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alpha-2a. Mult Scler, 5: 317-322.
161. NORTVEDT MW, RIISE T, MYER KJ, NYLAND HI. (2000a). Quality of life as a predictor for change in disability in multiple sclerosis. Neurology, 55: 51-54.
162. NORTVEDT MW, RIISE T, MYHR KM, NYLAND HI. (2000b). Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population. Med Care, 38: 1022-1028.
163. NUIJTEN MJ, HUTTON J. (2002). Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health, 5: 44-54.
164. NUNNALLY JC, BERNSTEIN IH. (1994). Psychometric theory, 3rd ed. New York: McGraw-Hill.
165. O'BRIEN B. (1987). Multiple Sclerosis. London: Office of Health Economics.
166. O'CONNOR P, LEE L, NG PT, NARAYANA P, WOLINSKY JS. (2001). Determinants of overall quality of life in secondary progressive MS: a longitudinal study. Neurology, 57: 889-891.
167. O'HARA L, CADBURY H, DE SOUZA L, IOE L. (2002). Evaluation of the effectiveness of professionally guided self-care for people with multiple sclerosis living in the community: a randomized controlled trial. Clin Rehabil, 16: 119-128.
168. PALMER S, BYFORD S, RAFTERY J. (1999). Types of economic evaluation. BMJ, 318: 1349.
169. PARKIN D, JACOBY A, MCNAMEE P, MILLER P, THOMAS S, BATES D. (2000). Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry, 68: 144-49.
170. PARKIN D, MCNAMEE P, JACOBY A, MILLER P, THOMAS S, BATES D. (1998). A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Assess, 2: iii-54.
171. PATRICK DL, DEYO RA. (1989). Generic and disease-specific measures in assessing health status and quality of life. Med Care, 27: S217-S232.
172. PATTI F, NICOLLETI F, CACOPARDO M, et al. (1999). Quality of life of multiple sclerosis patients. Self questionnaire (SF-36 and other instruments) (Abstract P189). Mult Scler, 5: S49.
173. PATTI F, CIANCIO MR, REGGIO E, LOPES R, PALERMO F, CACOPARDO M, REGGIO A. (2002). The impact of outpatient rehabilitation on quality of life in multiple sclerosis. J Neurol, 249: 1027-1033.
174. PATZOLD T, SCHWENGELBECK M, OSSEGE LM, MALIN JP, SINDERN E. (2001). Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis. Acta Neurol Scand, 105: 164-168.
175. PAYNE A. (2001). Nutrition and diet in the clinical management of multiple sclerosis. J Hum Nutr Diet, 14: 349-357.
176. PETAJAN JH, GAPPMAIER E, WHITE AT, SPENCER MK, MINO L, HICKS RW. (1996). Impact of aerobic training on fitness and quality of life in multiple sclerosis (see comments). Ann Neurol, 39: 432-441.
177. PETO V, JENKINSON C, FITZPATRICK R, GREENHALL R. (1995). The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res, 4: 241-248.
178. PEYSER JM, EDWARDS KR, POSER CM, FILSKOV SB. (1980). Cognitive function in patient with multiple sclerosis. Arch Neurol, 37: 577-579.
179. PFENNINGS LEMA, COHEN L, VAN DER PLOEG HM. (1997). Assessing the quality of life of patients with multiple sclerosis. In: Thompson AJ, Polman C, Hohlfeld R, eds. Multiple sclerosis: clinical challenges and controversies. London: Martin Dunitz: p. 195-210.
180. PFENNINGS L, COHEN L, MILLER D, et al. (1999a). Using the Short Form-36 with multiple sclerosis patients in five countries: a cross-cultural comparison. Psychol Rep, 85: 19-31.
181. PFENNINGS LE, VAN DER PLOEG HM, COHEN L, BRAMSEN I, POLMAN CH. (1999b). A comparison of responsiveness indices in multiple sclerosis patients. Qual Life Res, 8: 481-489.
182. PFENNINGS L, COHEN L, ADER H, POLMAN C, LANKHORST G, SMITS R, VAN DER PLOEG H. (1999c). Exploring differences between subgroups of multiple sclerosis patients in health-related quality of life. J Neurol, 246: 587-591.
183. PFENNINGS LE, VAN DER PLOEG HM, COHEN L, BRAMSEN I, POLMAN CH, LANKHORST GJ, VLEUGELS L. (1999d). A health-related quality of life questionnaire for multiple sclerosis patients. Acta Neurol Scand, 100: 148-155.
184. PINA LATORRE MA, ARA JR, MODREGO PJ, MARTIN M. (2001). Evaluation of handicap and socio-economic status in patients with multiple sclerosis: data from a population-based survey in the sanitary area of Calatayud, northern Spain. Wien Med Wochenschr, 151: 224-227.
185. POPE GC, URATO CJ, KULAS ED, KRONICK R, GILMER T. (2002). Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology, 58: 37-43.
186. POSER CM, RONTHAL M. (1991). Exercise and Alzheimer's disease, Parkinson's disease and multiple sclerosis. Phys Sports Med, 19: 85-92.
187. POSNER M, HOUSER HB. (1969). Economic aspects of multiple sclerosis. I. A method for classification of income of families of different sizes and compositions and its application in a longitudinal study of multiple sclerosis. J Chronic Dis, 22: 473-483.
188. POZZILLI C, BRUNETTI M, AMICOSANTE AMV et al. (2002). Home based management in multiple sclerosis: results of a randomised controlled trial. J Neurol Neurosurg Psychiatry, 73: 250-255.
189. QUINN J, MOORE M, BENSON DF, et al. (2002). A videotaped CIBIC for dementia patients: validity and reliability in a simulated clinical trial. Neurology, 58: 433-437.
190. RAO SM, LEO GJ, BERNARDIN L, UNVERZAGT F. (1991a). Cognitive dysfonction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology, 41: 685-691.
191. RAO SM, LEO GJ, ELLINGTON L, NAUERTZ T, BERNARDIN L, UNVERZAGT F. (1991b). Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology, 41: 692-696.
192. RIAZI A, HOBART JC, LAMPING DL et al. (2002). Multiple sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples. J Neurol Neurosurg Psychiatry, 73: 701-704.
193. RICE GP, OGER J, DUQUETTE P, FRANCIS GS, BÉLANGER M, LAPLANTE S, GRENIER J. F (1999). Treatment with interferon beta-lb improves quality of life in multiple sclerosis. Can J Neurol Sci, 26: 276-282.
194. RIECKMANN P. (2001). Early multiple sclerosis therapy in the effects of public health economics. Med Klin, 96: 17-21.
195. RITVO PG, FISCHER JS, MILLER DM, ANDREWS H, PATY D, LAROCCA NG. (1997). Multiple Sclerosis Quality of Life Inventory (MSQLI): A user's manual. New York, NY. National Multiple Sclerosis Society.
196. RODRIGUEZ M, SIVA A, WARD J, STOLP-SMITH K, O'BRIEN P, KURLAND L. (1994). Impairment, disability, and handicap in multiple sclerosis: a population-based study in Olmsted County, Mionnesota. Neurology, 44: 28-33.
197. ROTHWELL PM, MCDOWELL C, WONG CK, DORMAN PJ. (1997). Doctors and patients don't agree: cross sectional study of patients'and doctors'perceptions and assessements of disability in multiple sclerosis. BMJ, 314: 1580-1583.
198. ROULLET E, COSTE M, BASQUE V, MOCCATTI D, BENETON C, Millet MF, Marteau R. (1988). Echelle minimale d'invalidité et sclérose en plaques. Rev Neurol (Paris), 144: 805-816.
199. RUDICK RA, MILLER D, CLOUGH JD, GRAGG LA, FARMER RG (1992). Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol, 49: 1237-1242.
200. RUDICK R, ANTEL J, CONFAVREUX C, et al. (1997). Recommendations from the National Multiple Sclerosis Clinical Outcomes Assessment Task Force. Ann Neurol, 42: 379-382.
201. RUDICK RA, CUTTER G, BAIER M, et al. (2001). Use of the multiple sclerosis functional composite to predict disability in relapsing MS. Neurology, 56: 1324-1330.
202. SCHEINBERG LC, HOLLAND N, LAROCCA N, LAITIN P, BENNETT A, HALL A. (1980). Multiple sclerosis: earning a living. NY State J Med, 80: 1395-1400.
203. SCHWARTZ CE, COLE BF, GELBER RD. (1995). Measuring patient-centered outcomes in neurologic disease: Extending the Q-TWIST method. Arch Neurol, 52: 754-762.
204. SCHWARTZ CE, COULTHARD-MORRIS L, COLE B, VOLLMER T. (1997a). The quality-of-life effects of interferon-beta-1b in multiple sclerosis: An extended QTWIST analysis. Arch Neurol, 54: 1475-1480.
205. SCHWARTZ CE, COULTHARD-MORRIS L, COLE B, VOLLMER T. (1997b). The quality-of-life effects of interferon beta-1b in multiple sclerosis. Arch Neurol, 54: 1475-1480.
206. SCHWARTZ CE, BROTMAN S, LAROCCA N, LEE H. (1998). Patient perception of quality of care provided by specialists and generalists. Mult Scler, 4: 426-432.
207. SCHWARTZ L, KRAFT GH. (1999). The role of spouse responses to disability and family environment in multiple sclerosis. Am J Phys Med Rehabil, 78: 525-532.
208. SHARRACK B, HUGHES RAC. (1999). The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler, 5: 223-233.
209. SHARRACK B, HUGHES RAC, SOUDAIN S, DUUN G (1999). The psychometric properties of clinical rating scales used in multiple sclerosis. Brain, 122: 141-159.
210. SHAWARYN MA, SCHIAFFINO KM, LAROCCA NG, JOHNSTON MV. (2002). Determinants of health-related quality of life in multiple sclerosis: the role of illness intrusiveness. Mult Scler, 8: 310-318.
211. SKETRIS IS, BROWN M, MURRAY J, FISK JD, MCLEAN K. (1996). Drug therapy in multiple sclerosis: a study of Nova Scotia senior citizens. Clin Ther, 18: 303-318.
212. SLEVIN ML, PLANT H, LYNCH D, DRINKWATER J, GREGORY WM. (1988). Who should measure quality of life, the doctor or the patient? Br J Cancer, 57: 109-112.
213. SLOAN FA, VISCUSI WK, CHESSON HW, CONOVER CJ, WHETTEN-GOLDSTEIN K. (1998). Alternative-approaches to valuing intangible health losses: the evidence for multiple sclerosis. J Health Econ, 17: 475-497.
214. SOLARI A, FILIPPINI G, GASCO P, et al. (1999a). Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology, 52: 57-62.
215. SOLARI A, FILIPPINI G, MENDOZZI L, et al. (1999b). Validation of Italian multiple sclerosis quality of life-54 questionnaire. J Neurol Neurosurg Psychiatry, 67: 158-162.
216. SOLARI A, RADICE D. (2001). Health status of people with multiple sclerosis: a community mail survey. Neurol Sci, 22: 307-315.
217. SPRANGERS MAG, AARONSON NK. (1992). The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: a review. J Clin Epidemiol, 45: 743-760.
218. STOLP-SMITH KA, ATKINSON EJ, CAMPION ME, O'BRIEN PC, RODRIGUEZ M. (1998). Health care utilization in multiple sclerosis. A population based study in Olmsted County, MN. Neurology, 50: 1594-1600.
219. Stroke Unit Trialists'Collaboration. (1997). Collaborative systematic review of the randomized trials of organised impatient (stroke unit) care after stroke. BMJ, 314: 1151-1159.
220. STUIFBERGEN AK, BECKER H. (2001). Health promotion practices in women with multiple sclerosis: increasing quality and years of healthy life. Phys Med Rehabil Clin N Am, 12: 9-22.
221. SUTHERLAND HJ, LLEWELLYN-THOMAS HA, LOCKWOOD GA, TRITCHLER DL, TILL JE. (1989). Cancer patients: their desire for information and participation in treatment decisions. J R Soc Med, 82: 260-263.
222. SUTHERLAND G, ANDERSEN MB. (2001). Exercise and multiple sclerosis: physiological, psychological, and quality of life issues. J Sports Med Phys Fitness, 41: 421-432.
223. THE CANADIAN BURDEN OF ILLNESS STUDY GROUP. (1998a). Burden of illness of multiple sclerosis: Part I: Cost of illness. Can J Neurol Sci, 25: 23-30.
224. THE CANADIAN BURDEN OF ILLNESS STUDY GROUP. (1998b). Burden of illness of multiple sclerosis: Part II: Quality of life. Can J Neurol Sci, 25: 31-38.
225. THE EUROQOL GROUP. (1990). EuroQol - a new facility for the measurement of health-related quality of life. Health Policy, 16: 199-208.
226. THOMPSON AJ. (1999). Inequality in the availability of expensive treatments. J R Coll Physicians Lond, 33: 448-449.
227. THOMPSON AJ. (2000). The effectiveness of neurological rehabilitation in multiple sclerosis. J Rehabil Res Dev, 37: 455-461.
228. TISSOT E, WORONOFF-LEMSI MC. (2001). Sclérose en plaques: coût de la maladie. Rev Neurol (Paris), 157: 1169-1174.
229. TODD C. (1995). Putting multiple sclerosis under the «economic spotlight». Pharmacoresources, 36: 3-5.
230. TOLLEY K, WHYNES D. (1997). Interferon-β in multiple sclerosis. Can we control its costs? Pharmacoeconomics, 11: 210-215.
231. UPMEIER H, MILTENBURGER C. (2000). The cost of multiple sclerosis in Germany - A top down analysis. ISTAHC 2000, Den Haȧg, The Netherlands, June 18-21: Poster 153.
232. VERMERSCH P, MARISSAL JP. (2001). Les aspects médico-sociaux de la sclérose en plaques. Rev Neurol (Paris), 157: 1163-1168.
233. VERNAY D, GERBAUD L, BIOLAY S, et al. (2000). Qualité de vie et sclérose en plaques: validation de la version française francophone d'un auto-questionnaire, le SEP-59. Rev Neurol (Paris), 156: 247-263.
234. VERSIECK K, PACOLET J. (1996). The cost of care for patients with MS. Leuven: Biomed-MARCH Project, Catholic university of Leuven.
235. VICKREY BG, HAYS RD, HAROONI R, MYERS LW, ELLISON GW. (1995). A health related quality of life measure for multiple sclerosis. Qual Life Res, 4: 187-206.
236. VICKREY BG, HAYS RD, GENOVESE BJ, MYERS LW, ELLISON GW. (1997). Comparison of a generic to disease-targeted health-related quality-of-life measures for multiple sclerosis. J Clin Epidemiol, 50: 557-569.
237. VUKUSIC S. (1998). Sclérose en plaques: histoire naturelle et facteurs prédictifs de révolution vers le handicap. Thèse de Médecine, Faculté de Médecine RTH Laennec, Université Claude-Bernard Lyon 1, 103 p.
238. WALLEY T, BARTON S. (1995). A puchaser perspective of managing new drugs: Interferon beta as a case study. BMJ, 311: 796-799.
239. WARE JE, SHERBOURNE CD. (1992). Conceptual framework and item selection. Med Care, 30: 473-483.
240. WARE JE. (1996). The SF-36 Health Survey. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. (2nd ed). Philadelphia: Lippincott-Williams and Wilkins, p 337-345.
241. WARE JE. (2000). SF-36 Health Survey manual & interpretation guide. Ed: Lincoln RI; QualityMetric, Inc; Boston, Mass.: Health Assessment Lab.
242. WEINFELD FD, BAUM HM. (1984). The National Multiple Sclerosis Survey. Background and economic impact. Ann NY Acad Sci, 436: 469-471.
243. WEINSHENKER BG, BASS B, RICE GP, NOSEWORTHY J, CARRIERE W, BASKERVILLE J, EBERS GC. (1989). The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain, 112: 133-146.
244. WEINSTOCK-GUTTMAN B, BAIER M, LEEKWEN P, et al. (2002). A randomized study of low-fat diet with ω-3 fatty acid supplementation in patients with relapsing-remitting multiple sclerosis (RRMS). Neurology, 58: A461-A462.
245. WHETTEN-GOLDSTEIN K, SLOAN FA, CONOVER C, VISCUSI K, KULAS B, CHESSON H. (1996). The economic burden of multiple sclerosis. MS Management, 3: 33-37.
246. WHETTEN-GOLDSTEIN K, SLOAN FA, GOLDSTEIN LB, KULAS ED. (1998). A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler, 4: 419-425.
247. WHITAKER JN, MCFARLAND HF, RUDGE P, REINGOLD SC. (1995). Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler, 1: 37-47.
248. WILLIAMS A. (1990). Health economics, priority setting, and medical ethics: Implications for multiple sclerosis. Discussion paper 71. York: Centre for health Economics, University of York.
249. WILLIAMS MH, BOWIE C. (1993). Evidence of unmet need in the care of severely physically disabled adults. Br Med J, 306: 95-98.
250. WINTERHOLLER M, ERBGUTH F, NEUNDORFER B. (1997). Use of alternative medicine by patients with multiple sclerosis - users characterisation and patterns of use. Fortschr Neurol Psychiatr, 65: 555-561.